RXST

RxSight, Inc. [RXST] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

RXST Stock Summary

Top RXST Correlated Resources

RXST


Top 10 Correlated ETFs

RXST


Top 10 Correlated Stocks

RXST


In the News

07:14 08 Jun 2023 RXST

RxSight, Inc. (RXST) Q1 2023 Earnings Call Transcript

RxSight, Inc. (NASDAQ:RXST ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Alex Huang - Director, IR Ron Kurtz - President and CEO Shelley Thunen - CFO Conference Call Participants Allen Gong - JP Morgan Craig Bijou - Bank of America Joseph Conway - Needham & Co. Ryan Zimmerman - BTIG Steven Lichtman - Oppenheimer Lawrence Biegelsen - Wells Fargo Operator Welcome to the RxSight First Quarter 2023 Earnings Conference Call. Please be advised that today's conference is being recorded.

07:52 08 Jun 2023 RXST

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

RxSight, Inc. (RXST) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.54 per share a year ago.

04:05 08 Jun 2023 RXST

RxSight, Inc. to Present at the Bank of America Healthcare Conference

ALISO VIEJO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference.

04:05 08 Jun 2023 RXST

RxSight, Inc. to Report First Quarter Financial Results on May 9, 2023

ALISO VIEJO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

01:02 08 Jun 2023 RXST

Here's Why RxSight, Inc. (RXST) is a Great Momentum Stock to Buy

Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.

04:05 08 Jun 2023 RXST

RxSight, Inc. to Present at the Needham Healthcare Conference

ALISO VIEJO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Needham Healthcare Conference.

09:13 08 Jun 2023 RXST

4 Best Breakout Stocks to Buy Now for Superlative Returns

CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.

11:29 08 Jun 2023 RXST

How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%

The consensus price target hints at a 25.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

08:19 08 Jun 2023 RXST

RxSight, Inc. (RXST) Q4 2022 Earnings Call Transcript

RxSight, Inc. (NASDAQ:RXST ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Alex Huang – Investor Relations Ron Kurtz – President and Chief Executive Officer Shelley Thunen – Chief Financial Officer Conference Call Participants Craig Bijou – Bank of America Robbie Marcus – JPMorgan Ryan Zimmerman – BTIG David Saxon – Needham Operator Good day and thank you for standing by. Welcome to the RxSight Fourth Quarter Earnings Conference Call.

04:05 08 Jun 2023 RXST

RxSight, Inc. to Present at the Oppenheimer Healthcare Conference

ALISO VIEJO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Oppenheimer Healthcare Conference.

RXST Financial details

Company Rating
Neutral
Market Cap
884.55M
Income
-65.79M
Revenue
57.55M
Book val./share
4.58
Cash/share
4.87
Dividend
-
Dividend %
-
Employees
292
Optionable
No
Shortable
Yes
Earnings
09 May 2023
P/E
-12.35
Forward P/E
-
PEG
3.5
P/S
15.16
P/B
5.6
P/C
5.38
P/FCF
-13.55
Quick Ratio
11.2
Current Ratio
12.62
Debt / Equity
0.4
LT Debt / Equity
0.29
-
-
EPS (TTM)
-2.31
EPS next Y
-
EPS next Q
-
EPS this Y
-32.49%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
8.71%
EPS Q/Q
-16.07%
-
-
-
-
SMA20
23.81%
SMA50
62.5%
SMA100
100%
Inst Own
56.68%
Inst Trans
21.93%
ROA
-32%
ROE
-60%
ROC
-0.32%
Gross Margin
49%
Oper. Margin
-104%
Profit Margin
-114%
Payout
-
Shs Outstand
33.98M
Shs Float
22.13M
-
-
-
-
Target Price
-
52W Range
9.78-27.53
52W High
-3%
52W Low
+191%
RSI
66
Rel Volume
1.02
Avg Volume
302.64K
Volume
307.81K
Perf Week
0.61%
Perf Month
39.31%
Perf Quarter
147.31%
Perf Half Y
89.37%
-
-
-
-
Beta
-
-
-
Volatility
0.23%, 2.85%
Prev Close
1.99%
Price
26.19
Change
-0.3%

RXST Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0.120.771.661.77
Net income per share
6.721.45-3.57-2.41
Operating cash flow per share
-2.16-1.85-3.28-2.13
Free cash flow per share
-2.38-1.98-3.42-2.21
Cash per share
4.293.6211.693.82
Book value per share
-16.22-15.610.153.25
Tangible book value per share
-16.22-15.610.153.25
Share holders equity per share
-16.22-15.610.153.25
Interest debt per share
0.31.643.571.81
Market cap
300.55M305.17M153.28M350.48M
Enterprise value
298.1M321.93M173.85M383.64M
P/E ratio
2.3811.07-3.15-5.25
Price to sales ratio
134.1120.796.787.15
POCF ratio
-7.4-8.67-3.43-5.96
PFCF ratio
-6.72-8.09-3.29-5.72
P/B Ratio
-0.99-1.031.113.9
PTB ratio
-0.99-1.031.113.9
EV to sales
133.0221.937.697.83
Enterprise value over EBITDA
-7.39-10.44-3.3-6.21
EV to operating cash flow
-7.34-9.14-3.89-6.52
EV to free cash flow
-6.67-8.53-3.73-6.26
Earnings yield
0.420.09-0.32-0.19
Free cash flow yield
-0.15-0.12-0.3-0.17
Debt to equity
-1.36-1.340.390.67
Debt to assets
3.763.960.280.4
Net debt to EBITDA
0.06-0.54-0.39-0.54
Current ratio
10.677.0315.927.81
Interest coverage
-1.77K-69.42-14.34-12.8
Income quality
-0.32-1.280.920.88
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
13.191.491.080.53
Intangibles to total assets
0000
Capex to operating cash flow
0.10.070.040.04
Capex to revenue
-1.82-0.17-0.09-0.05
Capex to depreciation
-1.04-0.63-0.49-0.59
Stock based compensation to revenue
2.050.290.340.23
Graham number
49.5122.5328.5613.28
ROIC
-0.5-0.49-0.37-0.51
Return on tangible assets
1.140.27-0.25-0.44
Graham Net
-17.58-16.938.262.21
Working capital
81.74M69.9M165.22M117.32M
Tangible asset value
-304.61M-297.53M138.24M89.9M
Net current asset value
-324.84M-316.71M121.82M74.29M
Invested capital
-0.02-0.10.330.5
Average receivables
01.83M3.86M7.91M
Average payables
01.67M1.41M2.14M
Average inventory
07.75M8.16M11.43M
Days sales outstanding
128.5171.2478.5581.6
Days payables outstanding
197.6931.9134.1134.22
Days of inventory on hand
649233.19162.19195.64
Receivables turnover
2.845.124.654.47
Payables turnover
1.8511.4410.710.67
Inventory turnover
0.561.572.251.87
ROE
-0.41-0.09-0.35-0.74
Capex per share
-0.22-0.13-0.14-0.09

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
Revenue per share
0.330.410.460.570.55
Net income per share
-0.64-0.64-0.64-0.56-0.47
Operating cash flow per share
-0.55-0.54-0.55-0.49-0.56
Free cash flow per share
-0.56-0.58-0.57-0.51-0.59
Cash per share
5.244.674.083.784.87
Book value per share
4.493.993.473.214.58
Tangible book value per share
4.493.993.473.214.58
Share holders equity per share
4.493.993.473.214.58
Interest debt per share
1.681.691.691.661.46
Market cap
339.53M388.04M331.99M354.64M527.71M
Enterprise value
360.3M409.61M368.41M387.8M561.32M
P/E ratio
-4.82-5.49-4.69-5.68-8.89
Price to sales ratio
37.9734.1626.3222.0430.17
POCF ratio
-22.66-26.18-21.86-25.6-29.71
PFCF ratio
-22.11-24.4-21.05-24.95-28.51
P/B Ratio
2.763.533.463.943.64
PTB ratio
2.763.533.463.943.64
EV to sales
40.2936.0629.224.132.1
Enterprise value over EBITDA
-23.25-28.15-25.34-27.4-47.96
EV to operating cash flow
-24.04-27.63-24.26-27.99-31.6
EV to free cash flow
-23.46-25.76-23.36-27.28-30.32
Earnings yield
-0.05-0.05-0.05-0.04-0.03
Free cash flow yield
-0.05-0.04-0.05-0.04-0.04
Debt to equity
0.440.520.620.670.4
Debt to assets
0.30.340.380.40.28
Net debt to EBITDA
-1.34-1.48-2.5-2.34-2.87
Current ratio
15.1211.548.57.8112.62
Interest coverage
-15.64-13.9-12.28-10.33-8.69
Income quality
0.850.890.90.891.34
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.750.550.510.420.41
Intangibles to total assets
00000
Capex to operating cash flow
0.020.070.040.030.04
Capex to revenue
-0.04-0.1-0.05-0.02-0.04
Capex to depreciation
-0.36-1.03-0.59-0.38-0.75
Stock based compensation to revenue
0.30.260.230.180.19
Graham number
8.057.597.066.356.95
ROIC
-0.13-0.14-0.13-0.12-0.08
Return on tangible assets
-0.1-0.11-0.11-0.1-0.07
Graham Net
3.593.012.442.193.63
Working capital
150.49M136.93M122.79M117.32M172.79M
Tangible asset value
123.16M109.99M95.96M89.9M145.01M
Net current asset value
107.25M93.2M79.42M74.29M130.14M
Invested capital
0.360.410.470.50.31
Average receivables
5.24M6.26M7.95M9.99M11.81M
Average payables
2.14M2.93M3.72M3.38M3.16M
Average inventory
8.26M10.06M13.48M15.09M16.45M
Days sales outstanding
56.6254.5464.3561.2965.19
Days payables outstanding
44.9444.8851.7326.9546.96
Days of inventory on hand
147.48159.16190.14154.07228.28
Receivables turnover
1.591.651.41.471.38
Payables turnover
22.011.743.341.92
Inventory turnover
0.610.570.470.580.39
ROE
-0.14-0.16-0.18-0.17-0.1
Capex per share
-0.01-0.04-0.02-0.01-0.02

RXST Frequently Asked Questions

What is RxSight, Inc. stock symbol ?

RxSight, Inc. is a US stock , located in Aliso viejo of Ca and trading under the symbol RXST

What is RxSight, Inc. stock quote today ?

RxSight, Inc. stock price is $26.19 today.

Is RxSight, Inc. stock public?

Yes, RxSight, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap